Patents by Inventor Robert A. Lazarus

Robert A. Lazarus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR NEURAL DISEASE IMMUNOTHERAPY
    Publication number: 20140286963
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 25, 2014
    Applicant: GENENTECH, INC.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • PEPTIDE INHIBITORS OF BACE1
    Publication number: 20140228277
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: August 14, 2014
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • BACE1 antibodies
    Patent number: 8772457
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Method for Generating Potent Dendritic Cells
    Publication number: 20140056845
    Abstract: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.
    Type: Application
    Filed: April 16, 2012
    Publication date: February 27, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Robert Lazarus Modlin, Mirjam Schenk
  • Zymogen activators
    Patent number: 8623821
    Abstract: Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 7, 2014
    Assignee: Genentech, Inc.
    Inventors: Kyle E. Landgraf, Robert A. Lazarus
  • Variant Hhip1 protein and methods and uses thereof
    Patent number: 8623997
    Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: January 7, 2014
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20130143813
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: December 7, 2011
    Publication date: June 6, 2013
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • METHODS AND COMPOSITIONS FOR NEURAL DISEASE IMMUNOTHERAPY
    Publication number: 20120148599
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: November 9, 2011
    Publication date: June 14, 2012
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • HGF ? chain variants
    Patent number: 8110377
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20110177058
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: December 22, 2010
    Publication date: July 21, 2011
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • VARIANT HHIP1 PROTEIN AND METHODS AND USES THEREOF
    Publication number: 20110129457
    Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.
    Type: Application
    Filed: June 1, 2009
    Publication date: June 2, 2011
    Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
  • HGF BETA CHAIN VARIANTS
    Publication number: 20100210826
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Application
    Filed: April 27, 2010
    Publication date: August 19, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • HGF beta chain variants
    Patent number: 7737115
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: June 15, 2010
    Assignee: Genetech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20100040634
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • HUMAN DNASE I HYPERACTIVE VARIANTS
    Publication number: 20080293121
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Application
    Filed: July 1, 2008
    Publication date: November 27, 2008
    Applicant: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • CRYSTAL STRUCTURE OF THE HEPATOCYTE GROWTH FACTOR AND METHODS OF USE
    Publication number: 20080195366
    Abstract: The disclosure provides a crystal and crystal structure of the Hepatocyte Growth Factor Beta (HGF ?) Chain, as well as use of the crystal structure in the design, identification, and selection of modulators of HGF or Met activity.
    Type: Application
    Filed: March 27, 2008
    Publication date: August 14, 2008
    Inventors: Charles W. Eigenbrot, Daniel K. Kirchhofer, Robert A. Lazarus
  • Human DNase I hyperactive variants
    Patent number: 7407785
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive-variants of human DNase I.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Enzymes for the production of 2-keto-L-gulonic acid
    Patent number: 7256027
    Abstract: Mutants of 2,5-diketo-D-gluconic acid reductase A, an enzyme used to produce 2-keto-L-gulonic acid, a precursor of ascorbic acid (vitamin C) are prepared by site-directed mutagenesis. These mutants have increased catalytic activity, increased expression levels, and/or enhanced temperature stability.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: August 14, 2007
    Assignee: Rutgers, the State University of New Jersey
    Inventors: Robert A. Lazarus, Mark Hurle, Stephen Anderson, David B. Powers
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20070129301
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: October 2, 2006
    Publication date: June 7, 2007
    Inventors: Daniel Kirchhofer, Robert Lazarus, Xiaoyi Yao
  • FVIIa antagonists
    Patent number: 7164002
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: January 16, 2007
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Henry R. Maun